CLAUDIA GOLDENSTEIN SCHAINBERG

Prof. Dr. CLAUDIA GOLDENSTEIN SCHAINBERG


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 October 2022 in The Journal of Rheumatology
Verified
Journal Article
Closed access
PDF file
YLYing-Ying Leung
Ying-Ying Leung
TKTatiana V. Korotaeva
Tatiana V. Korotaeva
LCLiliana Candia
Liliana Candia
SPSusanne Juhl Pedersen
Susanne Juhl Pedersen
WBWilson Bautista-Molano
Wilson Bautista-Molano
OFOliver FitzGerald
Oliver FitzGerald
Objective: We aimed to compile evidence for the efficacy and safety of therapeutic options for the peripheral arthritis domain of psoriatic arthritis (PsA) for the revised 2021 Group in Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) treatment recommendations.Methods: A working group consisting of clinicians and patient research partners was convened. We reviewed the evidence from new randomized controlled trials (RCTs) for PsA treatment from February 19, 2013, to August 28, 2020. We used the Grading of Recommendations Assessment, Development, and Evaluation (GRADE)-informed approach to derive evidence for the classes of therapeutic options for 3 patient groups: (1) naïve to treatment, (2) inadequate response to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), and (3) inadequate response to biologic DMARDs (bDMARDs). Recommendations were derived through consensus meetings.Results: The evidence review included 69 RCTs. We derived GRADE evidence for each class of therapeutic options and achieved consensus for the recommendations. For patients naïve to treatment, the working group strongly recommends csDMARDs (methotrexate, sulfasalazine, leflunomide) and phosphodiesterase 4 inhibitors, and emphasizes regular assessment and early escalation to achieve treatment target. bDMARDs (tumor necrosis factor inhibitors [TNFi], interleukin 17 inhibitors [IL-17i], IL-12/23i, IL-23i) and Janus kinase inhibitors (JAKi) are also strongly recommended. For patients with inadequate response to csDMARDs, we strongly recommend TNFi, IL-17i, IL-12/23i, IL-23i, and JAKi. For those who had prior experience with bDMARDs, we strongly recommend a second TNFi, IL-17i, IL-23i, and JAKi. The evidence supporting nonpharmacological interventions was very low. An expert panel conditionally recommends adequate physical activity, smoking cessation, and diet to control weight gain.Conclusion: Evidence supporting optimal therapy for the peripheral arthritis domain of PsA was compiled for the revised 2021 GRAPPA treatment recommendations.

15 February 2013 in The Journal of Rheumatology
Verified
Journal Article
Open access
PDF file
RPRebecca L. Prowse
Rebecca L. Prowse
NDNicola Dalbeth
Nicola Dalbeth
AKArthur Kavanaugh
Arthur Kavanaugh
AAAdewale O. Adebajo
Adewale O. Adebajo
AGAngelo L. Gaffo
Angelo L. Gaffo
WTWilliam J. Taylor
William J. Taylor
Objective.: To identify a comprehensive list of features that might discriminate between gout and other rheumatic musculoskeletal conditions, to be used subsequently for a case-control study to develop and test new classification criteria for gout.Methods.: Two Delphi exercises were conducted using Web-based questionnaires: one with physicians from several countries who had an interest in gout and one with patients from New Zealand who had gout. Physicians rated a list of potentially discriminating features that were identified by literature review and expert opinion, and patients rated a list of features that they generated themselves. Agreement was defined by the RAND/UCLA disagreement index.Results.: Forty-four experienced physicians and 9 patients responded to all iterations. For physicians, 71 items were identified by literature review and 15 more were suggested by physicians. The physician survey showed agreement for 26 discriminatory features and 15 as not discriminatory. The patients identified 46 features of gout, for which there was agreement on 25 items as being discriminatory and 7 items as not discriminatory.Conclusion.: Patients and physicians agreed upon several key features of gout. Physicians emphasized objective findings, imaging, and patterns of symptoms, whereas patients emphasized severity, functional results, and idiographic perception of symptoms.

20 September 2022 in Joint Bone Spine
Verified
Journal Article
Closed access
CSCarla G.S. Saad
Carla G.S. Saad
MSMatheus S.R. Silva
Matheus S.R. Silva
PSPerceval D. Sampaio-Barros
Perceval D. Sampaio-Barros
JMJulio C.B. Moraes
Julio C.B. Moraes
CSCLAUDIA GOLDENSTEIN SCHAINBERG
CLAUDIA GOLDENSTEIN SCHAINBERG
EBEloisa Bonfa
Eloisa Bonfa

1 January 2020 in Clinics
Verified
Journal Article
Open access
PDF file
ASAndrea Yukie Shimabuco
Andrea Yukie Shimabuco
AMAna Cristina de Medeiros-Ribeiro
Ana Cristina de Medeiros-Ribeiro
RMRenata Miossi
Renata Miossi
KBKarina Rossi Bonfiglioli
Karina Rossi Bonfiglioli
JMJulio Cesar Bertacini de Moraes
Julio Cesar Bertacini de Moraes
CSCarla Gonçalves Schahin Saad
Carla Gonçalves Schahin Saad
OBJECTIVES: To retrospectively evaluate the performance and distinctive pattern of latent tuberculosis (TB) infection (LTBI) screening and treatment in patients with ankylosing spondylitis (AS) and psoriatic arthritis (PsA) under anti-tumor necrosis factor (TNF) therapy and determine the relevance of re-exposure and other risk factors for TB development. METHODS: A total of 135 and 83 patients with AS and PsA, respectively, were evaluated for LTBI treatment before receiving anti-TNF drugs via the tuberculin skin test (TST), chest radiography, and TB exposure [...] OBJECTIVES: To retrospectively evaluate the performance and distinctive pattern of latent tuberculosis (TB) infection (LTBI) screening and treatment in patients with ankylosing spondylitis (AS) and psoriatic arthritis (PsA) under anti-tumor necrosis factor (TNF) therapy and determine the relevance of re-exposure and other risk factors for TB development. METHODS: A total of 135 and 83 patients with AS and PsA, respectively, were evaluated for LTBI treatment before receiving anti-TNF drugs via the tuberculin skin test (TST), chest radiography, and TB exposure

3 October 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
CSClovis A. Silva
Clovis A. Silva
AMAna C. Medeiros-Ribeiro
Ana C. Medeiros-Ribeiro
LKLeonard V. K. Kupa
Leonard V. K. Kupa
EYEmily F. N. Yuki
Emily F. N. Yuki
SPSandra G. Pasoto
Sandra G. Pasoto
EBEloisa Bonfa
Eloisa Bonfa
The determination of durability and vaccine-associated protection is essential for booster doses strategies, however data on the stability of SARS-CoV-2 immunity are scarce. Here we assess anti-SARS-CoV-2 immunogenicity decay and incident cases six months after the 2nd dose of Sinovac-CoronaVac inactivated vaccine (D210) in 828 autoimmune rheumatic diseases patients compared with 207 age/sex-balanced control individuals. The primary outcome is the presence of anti-S1/S2 SARS-CoV-2 IgG at 6 months compared to 6 weeks after 2nd vaccine dose for decay evaluation. Secondary outcomes are presence of neutralizing antibodies, percent inhibition by neutralizing, geometric mean titers and cumulative incident cases at 6 months after 2nd dose. Anti-S1/S2 IgG positivity and titers reduce to 23.8% and 38% in patients (p < 0.001) during the six-month follow up and 20% and 51% in controls (p < 0.001), respectively. Neutralizing antibodies positivity and percent inhibition declines 41% and 54% in patients (p < 0.001) and 39.7% and 47% in controls (p < 0.001). Multivariate logistic regression analysis show males (OR = 0.56;95% CI0.40-0.79), prednisone (OR = 0.56; 95% CI0.41-0.76), anti-TNF (OR = 0.66;95% CI0.45-0.96), abatacept (OR = 0.29; 95% CI0.15-0.56) and rituximab (OR = 0.32;95% CI0.11-0.90) associate with a substantial reduction in IgG response at day 210 in patients. Although cellular immunity was not assessed, a decrease of COVID-19 cases (from 27.5 to 8.1/100 person-years; p < 0.001) is observed despite the concomitant emergence and spread of the Delta variant. Altogether we show a reduction in immunity 6-months of Sinovac-CoronaVac 2nd dose, particularly in males and those under immunosuppressives therapies, without a concomitant rise in COVID-19 cases. (CoronavRheum clinicaltrials.gov:NCT04754698).

19 January 2021 in Advances in Rheumatology
Verified
Journal Article
Open access
PDF file
RLRicardo da Cruz Lage
Ricardo da Cruz Lage
CMClaudia Diniz Lopes Marques
Claudia Diniz Lopes Marques
TOThauana Luiza Oliveira
Thauana Luiza Oliveira
GRGUSTAVO Gomes RESENDE
GUSTAVO Gomes RESENDE
CKCharles Lubianca Kohem
Charles Lubianca Kohem
MPMarcelo M Pinheiro
Marcelo M Pinheiro
Spondyloarthritis (SpA) is a group of chronic inflammatory systemic diseases characterized by axial and/or peripheral joints inflammation, as well as extra-articular manifestations. Over some decades, nonsteroidal anti-inflammatory drugs (NSAIDs) have been the basis for the pharmacological treatment of patients with axial spondyloarthritis (axSpA). However, the emergence of the immunobiologic agents brought up the discussion about the role of NSAIDs in the management of these patients. The objective of this guideline is to provide recommendations for the use of NSAIDs for the treatment of axSpA. A panel of experts from the Brazilian Society of Rheumatology conducted a systematic review and meta-analysis of randomized clinical trials for 15 predefined questions. The Grading of Recommendations, Assessment, Development and Evaluation methodology to assess the quality of evidence and formulate recommendations were used, and at least 70% agreement of the voting panel was needed. Fourteen recommendations for the use of NSAIDs in the treatment of patients with axSpA were elaborated. The purpose of these recommendations is to support clinicians’ decision making, without taking out his/her autonomy when prescribing for an individual patient.